Chindex Medical acquires 10 ViewRay MRIdian Systems for advanced cancer treatment
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China
The unit will have installed manufacturing capacity of over 15 million vials annually that includes lyophilized vials, all in the anti-cancer segment
If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine
Cipla and Ethris partner for the development of mRNA-based therapies
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
The cash and debt free consideration value is €370 million.
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
The scheme is subject to statutory and regulatory approvals as may be necessary.
Subscribe To Our Newsletter & Stay Updated